Natural killer (NK) cells play a major role in immune surveillance and in the early immune response to cancer and infections1,2. Beneficial anti-tumor responses have been observed, illustrating the safety profile and clinical potential of this treatment3,4. With an increasing availability of anti-cancer drugs, the role of NK cell-based approaches in novel combination therapies has rapidly escalated5,6.
The use of specific CliniMACS® Product Lines allows GMP-compliant manufacturing of NK cell products according to the needs given by a specific treatment concept.
Highly enriched NK cell products are generated by CD3 depletion followed by CD56 enrichment. A combined NK cell and natural killer T (NKT) cell product is produced by a single CD56 enrichment step. Heterogeneous NK cell products can be manufactured by either CD3 or TCRα/β depletion, optionally in combination with CD19 depletion. The latter two manufacturing strategies for NK cells allow co-enrichment of NK cells and accessory cells, such as monocytes and dendritic cells. In case of TCRα/β depletion, γ/δ T cells are also preserved within the NK cell product.
1.Chiossone, L. et al. (2018) Nat. Rev. Immunol. 18: 671–688.
2. Hammer, Q. et al. (2018) Nat. Immunol. 19: 800–808.
3. Miller, J. S. et al. (2005) Blood 105: 3051–3057.
4. Curti, A. et al. (2011) Blood 118: 3273–3279.
5. Bachanova, V. et al. (2018) Immunother. 67: 483–94.
6. Talleur, A. C. et al. (2017) Biol. Blood Marrow Transplant. 23: 1910–1917.